Q2 2024 Stereotaxis Inc Earnings Call Transcript
Key Points
- Stereotaxis Inc (STXS) has made significant progress in its strategic transformation, particularly with the introduction of GenesisX, which has obtained CE mark approval in Europe and has a 510(k) application submitted to the FDA.
- The company has a strong backlog of Genesis orders and expects significantly higher revenue recognition and cash flow in the second half of the year.
- Stereotaxis Inc (STXS) has a robust late-stage sales pipeline in all three key geographies (US, Europe, and China) and expects additional purchase orders for Genesis systems in the coming months.
- The acquisition of Access Point Technologies (APT) is expected to create strong sales synergies and strategic value, particularly in-house catheter development and manufacturing expertise.
- The company expects to end the year with approximately $13 million in cash and no debt, indicating a strong financial position to support upcoming milestones and commercialization efforts.
- Stereotaxis Inc (STXS) reported disappointing financial results for the first half of the year, with revenue for the second quarter totaling $4.5 million compared to $7.9 million in the prior year second quarter.
- The company's system revenue for the second quarter was only $0.2 million, reflecting minimal revenue recognized on system installations due to elongated customer construction projects.
- Operating loss and net loss for the second quarter of 2024 were $6 million and $5.8 million, respectively, compared to $5.3 million and $5 million in the previous year.
- The financial statements for the second quarter do not reflect any consolidation or impact from the APT acquisition beyond legal expenses incurred during the acquisition process.
- There is a risk that hospitals may delay purchasing decisions to wait for the next-generation GenesisX system, potentially impacting short-term sales of the current Genesis system.
Good afternoon, and welcome to the Stereotaxis, Inc. second quarter 2024 earnings conference call. Certain statements during the call and question-and-answer period to follow may relate to future events, expectations and, as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company in the future to be materially different from the statements that the company's executives make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q.
We assume no duty to update these statements. (Operator Instructions) As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
